http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26129996

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Comparative Study|Journal Article
endingPage 1325
issn 0008-543X
1097-0142
issueIdentifier 6
pageRange 1320-1325
publicationName Cancer
startingPage 1320
bibliographicCitation Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006 Mar 15;106(6):1320–5. doi: 10.1002/cncr.21701. PMID: 16470607.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_710a2d19a47989af064324b4de2a9f6b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5457d1a821039acf63adda6ef0be09e7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05de30059a7148306ae3aa650ef9f70f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_670a77a62359c962d900244c76a32115
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37addca178de74d7057a607ed8737920
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c084c68592a0dea7fd0042ae5251fac
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c48b0b1281b6b8f6bde20994101378fe
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc010e156a13806ae00368df24a7bacc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05c7dbd59f53dc1d584f901ea235e0b2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_29349321aae682b093ddefd3cee52f33
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_339f353dae8585f20d74248822904b27
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_48d83137fdc4dc4fa0b2f57568d9f470
date 2006-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1002/cncr.21701
https://pubmed.ncbi.nlm.nih.gov/16470607
isPartOf https://portal.issn.org/resource/ISSN/1097-0142
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771
https://portal.issn.org/resource/ISSN/0008-543X
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma
discusses http://id.nlm.nih.gov/mesh/M0028839
http://id.nlm.nih.gov/mesh/M0028682
http://id.nlm.nih.gov/mesh/M0028312
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D006689Q000188
http://id.nlm.nih.gov/mesh/D019380Q000008
http://id.nlm.nih.gov/mesh/D006509Q000517
http://id.nlm.nih.gov/mesh/D019259Q000008
http://id.nlm.nih.gov/mesh/D006515Q000187
http://id.nlm.nih.gov/mesh/D008228Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D006689Q000473
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D000293
http://id.nlm.nih.gov/mesh/D004305
http://id.nlm.nih.gov/mesh/D008228Q000473
http://id.nlm.nih.gov/mesh/D009367
http://id.nlm.nih.gov/mesh/D011322
http://id.nlm.nih.gov/mesh/D018943Q000627
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D009364Q000473
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D006509Q000453
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D002648
http://id.nlm.nih.gov/mesh/D000284
http://id.nlm.nih.gov/mesh/D006515Q000302
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D015996
http://id.nlm.nih.gov/mesh/D011379
http://id.nlm.nih.gov/mesh/D015994
http://id.nlm.nih.gov/mesh/D009364Q000188
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8388
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60825
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7987
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7989

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128324017
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275

Total number of triples: 72.